Amicus Completes Merger, Ends Nasdaq Listing and Reporting
TipRanks (Mon, 27-Apr 11:59 AM ET)
Amicus Gains Final Approval for BioMarin Acquisition Completion
TipRanks (Thu, 23-Apr 4:41 PM ET)
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
Globe Newswire (Fri, 20-Feb 4:01 PM ET)
Globe Newswire (Thu, 19-Feb 6:30 PM ET)
Globe Newswire (Tue, 3-Feb 8:00 AM ET)
Halper Sadeh LLC Reminds Shareholders of JHG, FOLD, RAPT of the Firm's Investigations
Globe Newswire (Mon, 2-Feb 4:49 PM ET)
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--JHG, FOLD, RAPT, and EXAS
PRNewswire (Mon, 2-Feb 3:30 PM ET)
Market Chameleon (Fri, 19-Dec 5:30 AM ET)
Market Chameleon (Fri, 19-Dec 3:40 AM ET)
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Amicus Therapeutics trades on the NASDAQ stock market under the symbol FOLD.
As of April 27, 2026, FOLD stock price was flat at $14.49 with million shares trading.
FOLD has a beta of 0.49, meaning it tends to be less sensitive to market movements. FOLD has a correlation of 0.03 to the broad based SPY ETF.
FOLD has a market cap of $4.55 billion. This is considered a Mid Cap stock.
Last quarter Amicus Therapeutics reported $185 million in Revenue and $.10 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.04.
In the last 3 years, FOLD traded as high as $14.57 and as low as $5.51.
The top ETF exchange traded funds that FOLD belongs to (by Net Assets): VTI, VB, IWM, XBI, VBK.
FOLD has outperformed the market in the last year with a return of +97.1%, while the SPY ETF gained +31.2%. However, in the most recent history, FOLD shares have underperformed the stock market with its stock returning +1.4% in the last 3 month period and +0.2% for the last 2 week period, while SPY has returned +3.1% and +4.2%, respectively.
FOLD support price is $14.48 and resistance is $14.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FOLD shares will trade within this expected range on the day.
